About CSL889

CSL889 is a new potential treatment under development for the symptoms of SCD.

Flyer for the CSL889 Clinical Trial (Ethics Comity Approved)

Flyer for the CSL889 Clinical Trial (Ethics Comity Approved)

CSL889 is a plasma derived Hemopexin, an important protein produced naturally in the body whose levels are decreased in patients with SCD.

CSL889 will be developed for the treatment of acute vasoocclusive crisis, a severe and painful complication in SCD patients.
It is given via blood channels (veins) over a period of approx. 1 hour or less.

The Study

• This is a clinical research study involving a single administration of the study drug, CSL889
• This is the first time that the study drug is being given to humans.
• This study will run for approximately 54 days
• This involves 9 outpatient visits and a 2 night residential stay
• Eligible participants may receive compensation for their participation in the study, plus reasonable travel expenses.
• Approx. 24 participants will take part in the study

Currently Open Clinical Trial Locations:

• King’s College Hospital – Denmark Hill London SE5 9RS
• Guy’s & St Thomas Hospital – Great Maze Pond London SE1 9RT
• UCLH – 235 Euston Road London NW1 2BU
• Manchester Royal Infirmary – Oxford Road, Manchester M13 9WL. Contact Number: 0161 906 7510
• MAC’s Early Phase Unit – Nelson Street Manchester M13 9NQ
  • Free phone 0800 917 7637
  • Link to register for the trial: https://bit.ly/3wCNx8A

If you are interested in this trial, you can also speak to your treating physicians who can get in touch with the participating sites on your behalf.